No results for ‘’
Aarey Drugs & Pharmaceuticals Ltd
₹102.75
(0.22%)
Sat, 26 Sept 2026, 05:15 am
Health Technology
Pharmaceuticals: Major
24.5KAarey Drugs & Pharmaceuticals Enterprise Value (EV)
| Particulars | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 19.03 | 17.96 | 14.59 | 68.24 | 39.87 | 17.19 | 21.38 | 36.95 | 33.55 | 20.40 | 10.33 | 5.37 | 8.33 | 15.21 | 15.93 | 24.24 | 23.67 |
| Price to book ratio | 1.76 | 1.58 | 0.53 | 0.58 | 0.78 | 0.53 | 0.66 | 1.30 | 3.74 | 1.57 | 0.78 | 0.34 | 0.55 | 0.85 | 0.51 | 0.94 | 0.69 |
| Price to sales ratio | 0.54 | 0.31 | 0.18 | 0.15 | 0.15 | 0.09 | 0.11 | 0.19 | 0.46 | 0.36 | 0.19 | 0.10 | 0.16 | 0.20 | 0.14 | 0.29 | 0.20 |
| Price to cash flow ratio | 488.29 | 0 | 0 | 0 | 11.21 | 0 | 13.22 | 93.24 | 433.76 | 0 | 0 | 0 | 18.73 | 42.35 | 0 | 0 | 106.48 |
| Enterprise value | 15.86Cr | 19.02Cr | 14.44Cr | 22.42Cr | 30.5Cr | 22.96Cr | 34.1Cr | 60.75Cr | 193Cr | 126Cr | 83.37Cr | 48.49Cr | 71.62Cr | 114Cr | 96.68Cr | 142Cr | 127Cr |
| Enterprise value to EBITDA ratio | 11.60 | 14.50 | 9.80 | 13.89 | 14.72 | 16.88 | 24.55 | 58.14 | 19.98 | 15.79 | 10.54 | 14.93 | 14.95 | 8.26 | 8.77 | 14.92 | 14.96 |
| Debt to equity ratio | 0.18 | 0.50 | 0.15 | 0.14 | 0.15 | 0.17 | 0.31 | 0.40 | 0.21 | 0.04 | 0.19 | 0.19 | 0.18 | 0.12 | 0.32 | 0.24 | 0.25 |
| Return on equity % | 0 | 9.21 | 5.08 | 1.04 | 1.99 | 3.09 | 3.11 | 3.58 | 12.75 | 9.46 | 7.84 | 6.48 | 6.81 | 6.17 | 3.26 | 3.74 | 2.97 |
Aarey Drugs & Pharmaceuticals Ltd Enterprise Value
The Aarey Drugs & Pharmaceuticals Ltd Enterprise Value is a key financial metric used by investors to evaluate Aarey Drugs & Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Aarey Drugs & Pharmaceuticals Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Aarey Drugs & Pharmaceuticals Ltd (NSE: AAREYDRUGS, BSE: 524412) is currently trading at ₹102.75, with a market capitalization of ₹289.38Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Aarey Drugs & Pharmaceuticals Ltd Enterprise Value is essential for fundamental analysis.
Aarey Drugs & Pharmaceuticals Ltd Enterprise Value Current Value
The current Aarey Drugs & Pharmaceuticals Ltd Enterprise Value stands at 127Cr.
The Aarey Drugs & Pharmaceuticals Ltd Enterprise Value has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Aarey Drugs & Pharmaceuticals Ltd Enterprise Value Historical Trend
The Aarey Drugs & Pharmaceuticals Ltd Enterprise Value has shown the following historical trend:
- 2024: 127Cr
- 2023: 142Cr
- 2022: 96.68Cr
- 2021: 114Cr
- 2020: 71.62Cr
The decline in Aarey Drugs & Pharmaceuticals Ltd Enterprise Value indicates improving financial efficiency or better earnings growth.
What Aarey Drugs & Pharmaceuticals Ltd Enterprise Value Indicates for Investors
The Aarey Drugs & Pharmaceuticals Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Aarey Drugs & Pharmaceuticals Ltd.
Aarey Drugs & Pharmaceuticals Ltd Enterprise Value Analysis Summary
The Aarey Drugs & Pharmaceuticals Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Aarey Drugs & Pharmaceuticals Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Aarey Drugs & Pharmaceuticals Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.